Ann E. Donnelly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ann E. Donnelly has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Erik Scott Wright
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, USA
2 shared publications - Brendan Sperling
Department of Chemistry, Princeton University, Princeton, NJ 08544
1 shared publication - Caroline Birer
CNRS, UMR8172 EcoFoG, AgroParisTech, Cirad, INRA, Université des Antilles, Université de Guyane, Cayenne, France
1 shared publication - Christiana N. Oji-Mmuo
Department of Pediatrics, Penn State College of Medicine, Hershey, USA
1 shared publication - Christopher Robert Anderton
Pacific Northwest National Laboratory
1 shared publication Grant S Murphy
Department of Chemistry, Princeton University, Princeton, New Jersey, USA
1 shared publication
Latest Publications
- Open Access
- 11 September 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (38)
Crystal structure and activity of a de novo enzyme, ferric enterobactin esterase Syn-F4
Producing novel enzymes that are catalytically active in vitro and biologically functional in vivo is a key goal of synthetic biology. Previously, we reported Syn-F4, the first de novo protein that meets both criteria. Syn-F4 hydrolyzed the siderophore ferric enterobactin, and expression of Syn-F4 allowed an inviable strain of Escherichia coli (Δ fes ) to grow in iron-limited medium. Here, we describe the crystal structure of Syn-F4. Syn-F4 forms a dimeric 4-helix bundle. Each monomer comprises two long α-helices, and the loops of the Syn-F4 dimer are on the same end of the bundle ( syn topology). Interestingly, there is a penetrated hole in the central region of the Syn-F4 structure. Extensive mutagenesis experiments in a previous study showed that five residues (Glu26, His74, Arg77, Lys78, and Arg85) were essential for enzymatic activity in vivo. All these residues are located around the hole in the central region of the Syn-F4 structure, suggesting a putative active site with a catalytic dyad (Glu26–His74). The complete inactivity of purified proteins with mutations at the five residues supports the putative active site and reaction mechanism. Molecular dynamics and docking simulations of the ferric enterobactin siderophore binding to the Syn-F4 structure demonstrate the dynamic property of the putative active site. The structure and active site of Syn-F4 are completely different from native enterobactin esterase enzymes, thereby demonstrating that proteins designed de novo can provide life-sustaining catalytic activities using structures and mechanisms dramatically different from those that arose in nature.
- 11 September 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (38)
Open AccessCrystal structure and activity of a de novo enzyme, ferric enterobactin esterase Syn-F4
Producing novel enzymes that are catalytically active in vitro and biologically functional in vivo is a key goal of synthetic biology. Previously, we reported Syn-F4, the first de novo protein that meets both criteria. Syn-F4 hydrolyzed the siderophore ferric enterobactin, and expression of Syn-F4 allowed an inviable strain of Escherichia coli (Δ fes ) to grow in iron-limited medium. Here, we describe the crystal structure of Syn-F4. Syn-F4 forms a dimeric 4-helix bundle. Each monomer comprises two long α-helices, and the loops of the Syn-F4 dimer are on the same end of the bundle ( syn topology). Interestingly, there is a penetrated hole in the central region of the Syn-F4 structure. Extensive mutagenesis experiments in a previous study showed that five residues (Glu26, His74, Arg77, Lys78, and Arg85) were essential for enzymatic activity in vivo. All these residues are located around the hole in the central region of the Syn-F4 structure, suggesting a putative active site with a catalytic dyad (Glu26–His74). The complete inactivity of purified proteins with mutations at the five residues supports the putative active site and reaction mechanism. Molecular dynamics and docking simulations of the ferric enterobactin siderophore binding to the Syn-F4 structure demonstrate the dynamic property of the putative active site. The structure and active site of Syn-F4 are completely different from native enterobactin esterase enzymes, thereby demonstrating that proteins designed de novo can provide life-sustaining catalytic activities using structures and mechanisms dramatically different from those that arose in nature.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3684
Predictive Value of Early Salivary MiRNAs in Preterm Infants With Bronchopulmonary Dysplasia
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3684
Predictive Value of Early Salivary MiRNAs in Preterm Infants With Bronchopulmonary Dysplasia
- 26 October 2022
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 88 (20) , e0092222
Balancing Trade-Offs Imposed by Growth Media and Mass Spectrometry for Bacterial Exometabolomics
Bacteria are capable of producing and secreting a rich diversity of specialized metabolites. Yet, much of their exometabolome remains hidden due to challenges associated with eliciting specialized metabolite production, labor-intensive sample preparation, and time-consuming analysis techniques.
- 26 October 2022
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 88 (20) , e0092222
Balancing Trade-Offs Imposed by Growth Media and Mass Spectrometry for Bacterial Exometabolomics
Bacteria are capable of producing and secreting a rich diversity of specialized metabolites. Yet, much of their exometabolome remains hidden due to challenges associated with eliciting specialized metabolite production, labor-intensive sample preparation, and time-consuming analysis techniques.
- Open Access
- 18 July 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (7) , e1010311
Sample-efficient identification of high-dimensional antibiotic synergy with a normalized diagonal sampling design
Antibiotic resistance is an important public health problem. One potential solution is the development of synergistic antibiotic combinations, in which the combination is more effective than the component drugs. However, experimental progress in this direction is severely limited by the number of samples required to exhaustively test for synergy, which grows exponentially with the number of drugs combined. We introduce a new metric for antibiotic synergy, motivated by the popular Fractional Inhibitory Concentration Index and the Highest Single Agent model. We also propose a new experimental design that samples along all appropriately normalized diagonals in concentration space, and prove that this design identifies all synergies among a set of drugs while only sampling a small fraction of the possible combinations. We applied our method to screen two- through eight-way combinations of eight antibiotics at 10 concentrations each, which requires sampling only 2,560 unique combinations of antibiotic concentrations. Antibiotic resistance is a growing public health concern, and there is an increasing need for methods to combat it. One potential approach is the development of synergistic antibiotic combinations, in which a mixture of drugs is more effective than any individual component. Unfortunately, the search for clinically beneficial drug combinations is severely restricted by the pace at which drugs can be screened. To date, most studies of combination therapies have been limited to testing only pairs or triples of drugs. These studies have identified primarily antagonistic drug interactions, in which the combination is less effective than the individual components. There is an acute need for methodologies that enable screening of higher-order drug combinations, both to identify synergies among many drugs and to understand the behavior of higher-order combinations. In this work we introduce a new paradigm for combination testing, the normalized diagonal sampling design, that makes identifying interactions among eight or more drugs feasible for the first time. Screening d drugs at m different combinations requires m ⋅ 2d samples under our design as opposed to md under exhaustive screening, while provably identifying all synergies under mild assumptions about antibiotic behavior. Scientists can use our design to quickly screen for antibiotic interactions, accelerating the pace of combination therapy development.
- 18 July 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (7) , e1010311
Open AccessSample-efficient identification of high-dimensional antibiotic synergy with a normalized diagonal sampling design
Antibiotic resistance is an important public health problem. One potential solution is the development of synergistic antibiotic combinations, in which the combination is more effective than the component drugs. However, experimental progress in this direction is severely limited by the number of samples required to exhaustively test for synergy, which grows exponentially with the number of drugs combined. We introduce a new metric for antibiotic synergy, motivated by the popular Fractional Inhibitory Concentration Index and the Highest Single Agent model. We also propose a new experimental design that samples along all appropriately normalized diagonals in concentration space, and prove that this design identifies all synergies among a set of drugs while only sampling a small fraction of the possible combinations. We applied our method to screen two- through eight-way combinations of eight antibiotics at 10 concentrations each, which requires sampling only 2,560 unique combinations of antibiotic concentrations. Antibiotic resistance is a growing public health concern, and there is an increasing need for methods to combat it. One potential approach is the development of synergistic antibiotic combinations, in which a mixture of drugs is more effective than any individual component. Unfortunately, the search for clinically beneficial drug combinations is severely restricted by the pace at which drugs can be screened. To date, most studies of combination therapies have been limited to testing only pairs or triples of drugs. These studies have identified primarily antagonistic drug interactions, in which the combination is less effective than the individual components. There is an acute need for methodologies that enable screening of higher-order drug combinations, both to identify synergies among many drugs and to understand the behavior of higher-order combinations. In this work we introduce a new paradigm for combination testing, the normalized diagonal sampling design, that makes identifying interactions among eight or more drugs feasible for the first time. Screening d drugs at m different combinations requires m ⋅ 2d samples under our design as opposed to md under exhaustive screening, while provably identifying all synergies under mild assumptions about antibiotic behavior. Scientists can use our design to quickly screen for antibiotic interactions, accelerating the pace of combination therapy development.
- 15 January 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 14 (3) , 253-255
A de novo enzyme catalyzes a life-sustaining reaction in Escherichia coli
Producing novel enzymes that are catalytically active in vitro and biologically functional in vivo is a key goal of synthetic biology. Here we describe Syn-F4, the first de novo protein that meets both criteria. Purified Syn-F4 hydrolyzes the siderophore ferric enterobactin, and expression of Syn-F4 allows an inviable strain of Escherichia coli to grow in iron-limited medium. These findings demonstrate that entirely new sequences can provide life-sustaining enzymatic functions in living organisms.
- 15 January 2018
- Published by Springer Nature in Nature Chemical Biology
- Vol. 14 (3) , 253-255
A de novo enzyme catalyzes a life-sustaining reaction in Escherichia coli
Producing novel enzymes that are catalytically active in vitro and biologically functional in vivo is a key goal of synthetic biology. Here we describe Syn-F4, the first de novo protein that meets both criteria. Purified Syn-F4 hydrolyzes the siderophore ferric enterobactin, and expression of Syn-F4 allows an inviable strain of Escherichia coli to grow in iron-limited medium. These findings demonstrate that entirely new sequences can provide life-sustaining enzymatic functions in living organisms.